{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-036052","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2023-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.086972+00:00","generated_at":"2026-06-19T16:11:23.167120+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Imara supplements merger proxy with lawsuit update and executive compensation details","bullets":["Lawsuit filed Nov 23, 2022 voluntarily dismissed Jan 19, 2023; Imara says meritless.","Pipeline chart updated: ELVN-002 advanced to Phase 1 clinical trial.","SVB Securities received $2.2M fees from Imara in past 2 years; disclosed as supplemental.","Post-merger: Kintz base salary to $550K, Collins to $465K, Hohl to $410K; bonus targets increased.","Enliven executives to receive change-in-control severance with 12-18 months salary and equity vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-036052","json":"https://secwatch.observer/filing/0001193125-23-036052.json","markdown":"https://secwatch.observer/filing/0001193125-23-036052.md","text":"https://secwatch.observer/filing/0001193125-23-036052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523036052/0001193125-23-036052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523036052/d410339d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T16:11:23.167120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}